
Office of Communications
and Public Liaison (OCPL)
Building 31, Room 5C27
31 Center Drive, MSC 2292
Bethesda, MD 20892
Phone: 301-496-1752
nianews3@mail.nih.gov
NIA is the lead Federal agency for supporting and conducting Alzheimer's disease research. For NIA background information on this topic see:
See NIA research news related to Alzheimer's disease below.
Limited time, limited reimbursement, and other health care barriers may lead to challenges when treating dementia patients, according to a study by the NIA-funded Alzheimer’s Disease Research Center at the University of California,...
A new analysis suggests that about 3.4 million Americans age 71 and older—one in seven people in that age group—have dementia, and 2.4 million of them have Alzheimer’s disease (AD). The study, supported by the National...
Few older people die with brains untouched by a pathological process, however, an individual’s likelihood of having clinical signs of dementia increases with the number of different disease processes present in the brain, according...
Alzheimer’s disease researchers may be able to reduce the time and expense associated with clinical trials, according to early results from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a public-private research...
The drugs naproxen and celecoxib did not reduce risk for Alzheimer’s disease in an analysis of data from a clinical trial sponsored by the National Institute on Aging (NIA), part of the National Institutes of Health. The trial...
A new imaging molecule that can detect and map plaques and tangles in the brains of people with Alzheimer’s disease could eventually lead to earlier diagnosis of the devastating disease, researchers at the University of California,...
Certain mental exercises can offset some of the expected decline in older adults' thinking skills and show promise for maintaining cognitive abilities needed to do everyday tasks such as shopping, making meals and handling finances,...
On Dec. 17, 2004, the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT) Steering Committee suspended treatments with two non-steroidal anti-inflammatory drugs (NSAIDs) in a large, three-arm, national Alzheimer’s...
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) -- a project developed by the National Institutes of Health (NIH) -- is seeking 800 older adults to participate in a study aimed at identifying biological markers of memory...
The search for new measures, or "biomarkers," to detect Alzheimer's disease (AD) before signs of memory loss appear has advanced an important step in a study by researchers at Washington University in St. Louis, MO, and the...